Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
platelet-rich plasma + platelet-poor plasma
- Development stage
- Unknown
- Lead developer
- Shahid Beheshti University of Medical Sciences
- Administration
- Intraarticular, Intradermal, Intramuscular, Intralesional, Topical
01
Overview
Platelet-rich plasma (PRP) and platelet-poor plasma (PPP) are blood components with different platelet concentrations used in regenerative medicine. PRP contains a high concentration of platelets (6-8 times normal levels) that release growth factors to stimulate tissue healing. PPP has a very low platelet count (<10 x 10³/μL) but contains fibrinogen and other proteins that can form fibrin-rich clots to facilitate cell migration and attachment. When used together, they provide complementary benefits: PRP delivers concentrated growth factors for accelerated healing, while PPP offers anti-inflammatory properties and provides a scaffold for tissue regeneration. This combination is used to treat various musculoskeletal injuries, promote wound healing, and support tissue regeneration.
- Other names
- PRP + PPP
02
Targets
EGFR (Epidermal growth factor receptor)IGF-1R (Insulin-like growth factor 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)TGFBR3 (TGF-β receptor type III)VEGFR2 (Vascular endothelial growth factor receptor 2)MET (Mesenchymal-epithelial transition factor receptor)GPIIb/IIIa (Integrin alpha-IIb/beta-3)
Beyond the preview
Go deeper on platelet-rich plasma + platelet-poor plasma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on platelet-rich plasma + platelet-poor plasma.